Patent Law Weblog
Year: 2020
-
October 13, 2020 – "An In-House Counsel’s Guide to Product Clearance: Best Practices in Freedoms-to-Operate, Landscaping and Opinions of Counsel" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT) October 13, 2020 – "Preparing & Prosecuting Patents That Stand Up To Challenge" (LexisNexis IP and IPWatchdog) – 12:00 pm (ET) October…
-
American Conference Institute (ACI) will be holding its 4th Annual Summit on Life Sciences IP Due Diligence on November 9-10 as a VIRTUAL conference. The conference will begin with a Pre-Conference Primer at 8:00 am Monday, November 9th, entitled "Life Science Due Diligence 101 – Preparing Your Due Diligence Checklist and Managing the Process from…
-
LexisNexis IP and IPWatchdog and will be offering a webinar entitled "Myths of Litigated Patents" on October 15, 2020 at 12:00 pm (ET). Dr. Sean Tu, Professor, WVU College of Law; Megan McLoughlin of LexisNexis® IP; and Gene Quinn of IPWatchdog will discuss whether patent examiners who issue litigated patents have common characteristics? While intuition…
-
McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "An In-House Counsel’s Guide to Product Clearance: Best Practices in Freedoms-to-Operate, Landscaping and Opinions of Counsel" on October 13, 2020 from 10:00 am to 11:15 am (CT). In this presentation, MBHB attorneys Grantland Drutchas and Jason Kray will address the steps in-house…
-
LexisNexis IP and IPWatchdog and will be offering a webinar entitled "Preparing & Prosecuting Patents That Stand Up To Challenge" on October 13, 2020 at 12:00 pm (ET). Todd Van Thomme of Nyemaster Goode P.C., Kristin Murphy of Honigman LLP, and Bernie Tomsa of Brooks Kushman P.C. will discuss: (1) Pros and cons of having…
-
What Quantum of Culpable Conduct Is Required for an ANDA Applicant to Induce Infringement? By Kevin E. Noonan — The back-and-forth, (almost) cat-and-mouse-like competition between branded innovator and generic drug makers sanctioned under the Hatch-Waxman Act has been on-going for over thirty years. As part of this regime, Congress has provided a pathway for generic…
-
By Kevin E. Noonan — In the Patent Trial and Appeal Board's decision on motions issued September 10th in Interference No. 106,115 (see "PTAB Decides Parties' Motions in CRISPR Interference") between Senior Party The Broad Institute, Harvard University, and the Massachusetts Institute of Technology (collectively, "Broad") and Junior Party the University of California/Berkeley, the University of…
-
By Kevin E. Noonan — In the Patent Trial and Appeal Board's decision on motions issued September 10th in Interference No. 106,115 (see "PTAB Decides Parties' Motions in CRISPR Interference") between Senior Party The Broad Institute, Harvard University, and the Massachusetts Institute of Technology (collectively, "Broad") and Junior Party the University of California/Berkeley, the University of…
-
By Kevin E. Noonan — Novelty is perhaps the principal, most fundamental requirement for patentability, and depriving the public of anything in the prior art must be avoided. The Federal Circuit recently reinforced the primacy of these rubrics in Biogen MA, Inc. v. EMD Serono, Inc. The issues arose in litigation over Biogen's Rebif* product…
-
By Kevin E. Noonan — For those with long memories, last August the Patent Trial and Appeal Board received proposed motions from the parties (University of California/Berkeley, the University of Vienna, and Emmanuelle Charpentier, Junior Party, and The Broad Institute, Massachusetts Institute of Technology, and Harvard University, Senior Party) in Interference No. 106,115. Thereafter, the…
Patent Docs 